Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry, announced the appointment of Jim Anthony to the expanded role of Chief Commercial Officer (CCO) and President, Parexel Biotech, further strengthening the company’s customer focus and its ability to drive growth and value.  Anthony has served as the global leader for Parexel Biotech since its inception in 2019, and most recently as President and Global Head, Parexel Biotech.

As Chief Commercial Officer and President, Parexel Biotech, Anthony will oversee both biotech and pharmaceutical customer strategy and relationships globally, leveraging the company’s comprehensive suite of solutions and industry-leading therapeutic expertise across Phase I-IV clinical development to accelerate and advance their life-changing therapies to market.

Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role. He joined Parexel in 2010 as Vice President, North America Business Development, and since that time has held various leadership roles of increasing responsibility, including Corporate Vice President, Enterprise Account Leader, where he directly managed two of the company’s largest pharma customers, and Executive Vice President and Global Head, Parexel Biotech, before being appointed as President and Global Head, Parexel Biotech in 2023.